Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity

Inclusion Criteria: * Eighteen years of age or older * Employee/member of: municipal or provincial police service, emergency medical services, fire services, public transport service, health service, food manufacturing facility Exclusion Criteria: * Prior intravesical BCG or intradermal BCG, with the exception of tuberculosis vaccination in childhood. * Previous known history of latent or active tuberculosis * Known kidney, liver or blood disorders which impairs organ and marrow function * Chronic administration of steroids (\>10 mg prednisone) at the time of randomization * Current or planned concomitant biologic therapy in the next 7 months. * Known hypersensitivity or allergy to components of VPM1002 * Pregnant or planning to become pregnant in the future 7 months. * Breastfeeding. * Current suspected viral or bacterial infection. * Body temperature \> 38° C * Participation in another interventional study with potentially conflicting medication within 30 days before screening. * The presence of an impaired immune response irrespective of whether this impairment is congenital or caused by disease, drugs or other therapy (e.g., anti-TNF therapy, methotrexate, azathioprine, antimalarials). * Active malignancy requiring treatment. * Known positive HIV serology. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to BCG vaccine. * Previous positive COVID-19 confirmed infection. * Uncontrolled intercurrent illness. * Psychiatric illness/social situations that would limit compliance with study requirements.